Français | English

Agence nationale sanitaire et scientifique en cancérologie

Accueil Nota Bene Cancer V2 Numéro 137 du 22 May 2012 Traitements BREADCRUMB PUBLICATION

Print

Nota Bene Cancer Fiche de publication

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia

Menée in vitro, à l'aide de xénogreffes et sur des singes cynomolgus, cette étude évalue l'activité d'un anticorps monoclonal appelé CDX-1127 dans les leucémies et lymphomes CD27+

  • Clinical Cancer Research, sous presse, 2012 (résumé)

Résumé en anglais :
Purpose: The TNF receptor superfamily member, CD27 is best known for its important role in T cell immunity, but is also recognized as a cell-surface marker on a number of B and T cell malignancies. In this report, we describe a novel human monoclonal antibody (mAb) specific for CD27 with properties that suggest a potential utility against malignancies that express CD27. Experimental Design: The fully human mAb 1F5 was generated using human Ig transgenic mice and characterized by analytical and functional assays in vitro. Severe combined immunodeficiency (SCID) mice inoculated with human CD27-expressing lymphoma cells were administered 1F5 to investigate direct anti-tumor effects. A pilot study of 1F5 was conducted in non-human primates to assess toxicity. Results: 1F5 binds with high affinity and specificity to human and macaque CD27, and competes with ligand binding. 1F5 activates T cells only in combination with T cell receptor stimulation, and does not induce proliferation of primary CD27-expressing tumor cells. 1F5 significantly enhanced the survival of SCID mice bearing Raji or Daudi tumors, which may be mediated through direct effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). Importantly, administration of up to 10 mg/kg of 1F5 to cynomolgus monkeys was well tolerated without evidence of significant toxicity or depletion of circulating lymphocytes. Conclusions: Collectively, the data suggest that the human mAb 1F5, which has recently entered clinical development under the name CDX-1127, may provide direct anti-tumor activity against CD27 expressing lymphoma or leukemia, independent of its potential to enhance immunity through its agonistic properties.

NBC n° 137 du 22 May 2012

Mots clés : Leucémie; Traitements (Traitements systémiques : découverte et développement)

Recherche de publications

Recherche avancée

Widget

 

Archives

Formulaire d’abonnement

Pour recevoir gratuitement chaque nouveau numéro de Nota Bene Cancer par courriel :

S'abonner

Sources

Pour visualiser l'ensemble des sources alimentant le Nota Bene Cancer :

Accéder au portail des sources du NBC

Foire aux questions

Pour trouver les réponses aux questions que vous vous posez sur Nota Bene Cancer :

Accéder à la F.A.Q.